Source comparison
CJC-1295 No DAC Blood Work Labs Check Before After: Comparison Table
IGF-1 115–300 ng/mL (age-dependent) +20–40% elevation from baseline >400 ng/mL or <baseline Efficacy confirmation. IGF-1 elevation proves GH upregulation; excess suggests dose reduction needed Fasting Glucose <100 mg/dL Stable or slight elevation (+5–10 mg/dL)
This comparison does not assign a generated winner or score.
- IGF-1
- 115–300 ng/mL (age-dependent)
- +20–40% elevation from baseline
- >400 ng/mL or <baseline
- Efficacy confirmation. IGF-1 elevation proves GH upregulation; excess suggests dose reduction needed
- Fasting Glucose
- <100 mg/dL
- Stable or slight elevation (+5–10 mg/dL)
- >110 mg/dL
- GH-induced insulin resistance. Reduce dose or discontinue protocol
- Fasting Insulin
- <10 μIU/mL
- Stable or slight elevation (+2–5 μIU/mL)
- >15 μIU/mL
- Metabolic stress marker. Monitor for pre-diabetic glucose dysregulation
- LDL Cholesterol
- <130 mg/dL
- Slight reduction (−5–15 mg/dL)
- Increase >10% from baseline
- Unexpected. Suggests dietary confounding or unrelated metabolic dysfunction
- Triglycerides
- <150 mg/dL
- Reduction (−10–20%)
- GH promotes lipolysis. Elevation indicates poor dietary compliance or metabolic issue
- Liver Enzymes (ALT/AST)
- <40 U/L
- Stable or transient elevation (<10 U/L)
- >60 U/L
- Hepatotoxicity signal. Investigate peptide purity or reduce dose
- TSH
- 0.5–4.5 mIU/L
- Stable
- Suppressed <0.5 or elevated >5.0 mIU/L
- GH-thyroid interaction. Possible T4-to-T3 conversion increase or thyroid medication conflict
- Prolactin
- <15 ng/mL (males), <25 ng/mL (females)
- >20 ng/mL (males), >30 ng/mL (females)
- Rare but possible GH-mediated prolactin elevation. Monitor for gynecomastia or libido changes